Phase III APECS study of MK 8931 halted in Alzheimer's disease, the second trial of the drug to be cancelled.- Merck Inc.
Merck Inc announced that it will be stopping protocol 019, also known as the APECS study, a Phase III study evaluating MK 8931 (verubecestat), an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with prodromal Alzheimer's disease (AD).
The decision to stop the study follows a recommendation by the external Data Monitoring Committee (eDMC), which assessed overall benefit/risk during a recent interim safety analysis. The eDMC concluded that it was unlikely that positive benefit/risk could be established if the trial continued. Data from the APECS study will be presented at an upcoming medical meeting.
This decision comes 1 year after Merck Inc stopped protocol 017, also known as the EPOCH study, under similar conditions.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma